期刊
ADVANCED DRUG DELIVERY REVIEWS
卷 130, 期 -, 页码 50-57出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.addr.2018.06.014
关键词
Pancreatic cancer; Nanotherapy; Engineered approach; Stroma
资金
- U.S. Public Health Service Grant [U01CA198846]
While chemotherapy is the only approved non-surgical option for the majority of pancreatic cancer patients, it rarely results in a cure. The failure to respond to chemotherapy is due to the presence of an abundant dysplastic stroma that interferes in drug delivery and as a result of drug resistance. It is appropriate, therefore, to consider the stromal contribution to the resistance to chemotherapy and sidestepping this barrier with nanocarriers that improve survival outcome. In this paper, we provide a short overview of the role of the stroma in chemotherapy resistance, including the use of nanocarriers to negate this barrier. We provide a perspective and guidance towards the implementation of nanotherapeutic approaches to improve therapeutic delivery and efficacy of PDAC management. (C) 2018 Published by Elsevier B.V.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据